ImmuCell Co. (NASDAQ:ICCC) Sees Significant Drop in Short Interest

ImmuCell Co. (NASDAQ:ICCC) was the target of a significant decline in short interest in the month of September. As of September 15th, there was short interest totalling 8,500 shares, a decline of 54.3% from the August 31st total of 18,600 shares. Based on an average daily trading volume, of 35,800 shares, the short-interest ratio is currently 0.2 days. Currently, 0.2% of the company’s shares are short sold.

ImmuCell Trading Down 1.7 %

ICCC traded down $0.06 during trading on Friday, reaching $3.55. 16,710 shares of the stock traded hands, compared to its average volume of 18,958. The stock’s 50-day moving average is $3.79 and its 200 day moving average is $4.43. ImmuCell has a 12 month low of $3.34 and a 12 month high of $5.59. The company has a quick ratio of 0.77, a current ratio of 2.37 and a debt-to-equity ratio of 0.42. The stock has a market capitalization of $27.73 million, a PE ratio of -6.96 and a beta of 0.56.

ImmuCell (NASDAQ:ICCC) last released its earnings results on Tuesday, August 13th. The biotechnology company reported ($0.20) EPS for the quarter. ImmuCell had a negative return on equity of 16.35% and a negative net margin of 17.44%. The business had revenue of $5.47 million for the quarter.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in ImmuCell stock. Mesirow Financial Investment Management Inc. acquired a new stake in shares of ImmuCell Co. (NASDAQ:ICCC) in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 12,178 shares of the biotechnology company’s stock, valued at approximately $65,000. Mesirow Financial Investment Management Inc. owned approximately 0.16% of ImmuCell as of its most recent SEC filing. 13.47% of the stock is currently owned by hedge funds and other institutional investors.

About ImmuCell

ImmuCell Corporation, an animal health company, develops, manufactures, and sells products that enhance the health and productivity of dairy and beef cattle in the United States and internationally. The company operates through two segments, Scours and Mastitis. It offers First Defense, an orally delivered scours preventive product for calves with claims against E.